Uploaded November 2025 | Updated November 2026, 13 hours ago
Why do so many disease-driving proteins remain out of reach for today’s medicines?
In this Science is Boss conversation, Bayer CEO Bill Anderson speaks with Aleksandra Rizo, CEO of Vividion Therapeutics, about why many disease targets have long been considered “undruggable” — and how emerging small molecule screening approaches are helping researchers explore new possibilities.
You’ll hear an accessible overview of what can make a protein difficult to target (for example, smooth or flexible surfaces without a clear binding pocket), why small molecules remain an important modality (including oral dosing potential and well-established development pathways), and how Vividion’s platform approach screens across thousands of proteins to look for previously unrecognized binding sites.
In this video:
- Why many disease-driving proteins have historically been hard to target
- How small molecule medicines work at a high level
- Binding pockets and why they matter in drug design
- A platform approach to identifying potential new binding sites
- Examples discussed: Werner (WRN), squamous non-small cell lung cancer, colorectal cancer
- Timelines: what “10–15 years” can look like from discovery to patients
A science-forward discussion on how small molecule discovery is evolving — and what it may mean for future research and potential therapies.
Why do so many disease-driving proteins remain out of reach for today’s medicines?
In this Science is Boss conversation, Bayer CEO Bill Anderson speaks with Aleksandra Rizo, CEO of Vividion Therapeutics, about why many disease targets have long been considered “undruggable” — and how emerging small molecule screening approaches are helping researchers explore new possibilities.
You’ll hear an accessible overview of what can make a protein difficult to target (for example, smooth or flexible surfaces without a clear binding pocket), why small molecules remain an important modality (including oral dosing potential and well-established development pathways), and how Vividion’s platform approach screens across thousands of proteins to look for previously unrecognized binding sites.
In this video:
- Why many disease-driving proteins have historically been hard to target
- How small molecule medicines work at a high level
- Binding pockets and why they matter in drug design
- A platform approach to identifying potential new binding sites
- Examples discussed: Werner (WRN), squamous non-small cell lung cancer, colorectal cancer
- Timelines: what “10–15 years” can look like from discovery to patients
A science-forward discussion on how small molecule discovery is evolving — and what it may mean for future research and potential therapies.










